PedAM

Pediatric Disease Annotations & Medicines

Disease	malabsorption syndrome
Phenotype	C0021831\|intestinal disease
Sentences	15
PubMedID- 23326550	Subjects were excluded if they had history of cardiovascular disease including peripheral atherosclerosis, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, positivity for antibodies to hepatitis c virus (hcv) or hepatitis b surface antigen (hbsag), and liver or kidney failure.
PubMedID- 22011411	Other exclusion criteria were history or clinical evidence of coronary and/or valvular heart disease, congestive heart failure, hyperlipidemia, hyperuricemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, or chronic pancreatitis; history of malignant disease, alcohol or drug abuse, or liver or kidney failure; and treatments able to modify glucose or ua metabolism.
PubMedID- 22399698	Subjects were excluded if they had gastrointestinal diseases associated with bleeding or malabsorption, chronic pancreatitis, history of any malignant disease, history of drug abuse, positivity for antibodies to hepatitis c virus or hepatitis b surface antigen, and anemia, defined according to the world health organization criteria as a hemoglobin concentration <13 g/dl in men and <12 g/dl in women.
PubMedID- 24555478	Other exclusion criteria were history or clinical evidence of coronary and/or valvular heart disease, congestive heart failure, hyperlipidaemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, or chronic pancreatitis; history of malignant disease, alcohol or drug abuse, or liver or kidney failure; and any treatments interfering with glucose or vitamin d metabolism.
PubMedID- 22545220	The diagnostic criteria for nphpt were as follows: apart from normal serum calcium and high pth levels, serum 25ohd levels above 30 ng/ml, absence of bisphosphonates, thiazide diuretics, anticonvulsants or lithium use, glomerular filtration rate greater than 60 ml/min, using the formula modification of diet in renal disease (mdrd), and the absence of other metabolic bone diseases or gastrointestinal diseases associated with malabsorption or liver disease.
PubMedID- 21922352	It may be the result of inadequate intake or malabsorption in children with gastrointestinal diseases including cystic fibrosis, α1-antitrypsin deficiency, and biliary atresia.
PubMedID- 21515837	Other exclusion criteria were history or clinical evidence of coronary and valvular heart disease, congestive heart failure, hyperlipidemia, peripheral vascular disease, chronic gastrointestinal disease associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, and treatment to modify glucose metabolism.
PubMedID- 23203035	Subjects were excluded if they had a history of arterial hypertension, other exclusionary criteria were chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, and treatments able to modify glucose metabolism.
PubMedID- 22164268	Subjects, aged 23–70 years, were excluded if they had history of cardiovascular disease, including peripheral atherosclerosis, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, or received treatments able to modify glucose metabolism including glucose-lowering, lipid-lowering and antihypertensive therapy.
PubMedID- 26155986	Other causes of shpt, such renal failure, hypercalciuria, gastrointestinal diseases associated with malabsorption and other metabolic bone diseases that could affect pth levels (e.g.
PubMedID- 21911775	Other exclusion criteria were history or clinical evidence of coronary or valvular heart disease, congestive heart failure, hyperlipidemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, and treatments able to modify glucose metabolism.
PubMedID- 23028545	Other exclusion criteria were history or clinical evidence of coronary and valvular heart disease, congestive heart failure, hyperlipidemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure and treatments able to modify glucose metabolism.
PubMedID- 26243847	Also, patients with gastrointestinal disease associated with malabsorption were excluded.
PubMedID- 23475190	Enrolment into the sub-cohort was based on the exclusion criteria of any pre-existing conditions that would impact on bmc, including rickets, tuberculosis, cancer, a history of endocrine disease, gastrointestinal disease associated with malabsorption, and regular medication use, specifically corticosteroids, anti-epileptic drugs, calcium and/or vitamin d supplementation.
PubMedID- 21076576	Subjects were excluded from the study if they had a history of cardiovascular disease including peripheral atherosclerosis, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, and treatments able to modify glucose metabolism, such as steroid.

Page: 1